SCHEMBL1019833

SCHEMBL1019833

CC(=O)c1cc(Br)cc(F)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 3/20 0.42
AKR1C1 Q04828 3/20 0.42
AKR1C3 P42330 2/20 0.42
AKR1C4 P17516 1/20 0.42
DGAT1 O75907 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NSD2 O96028 1/20 0.39
POLB P06746 1/20 0.39
MCL1 Q07820 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
LCK P06239 1/20 0.38
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16461500 0.82 CES2 (0.42) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL1516725 0.82 AKR1C2 (0.64) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL30673278 0.82 AKR1C2 (0.64) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL30931173 0.80 MEN1 (0.39) AKR1C2AKR1C1DGAT1KMT2AMEN1
SCHEMBL4350297 0.80 DGAT1 (0.58) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL24992821 0.80 MEN1 (0.39) AKR1C2AKR1C1DGAT1KMT2AMEN1
SCHEMBL23087740 0.80 HDAC1 (0.41) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL22823904 0.79 HSP90AB1 (0.41) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL29365349 0.79 HSP90AB1 (0.41) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1
SCHEMBL1516592 0.79 GAA (0.44) AKR1C2AKR1C1AKR1C3AKR1C4DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 US disclosed
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 US disclosed
WO-2025049994-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-03-06 WO disclosed
US-20240166661-A1 Spiropiperidine Derivatives CEPHALON LLC 2024-05-23 US disclosed
US-11878982-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2024-01-23 US disclosed
US-20210284651-A1 Spiropiperidine Derivatives CEPHALON LLC 2021-09-16 US disclosed
US-11046707-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2021-06-29 US disclosed
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 US disclosed
EP-3554637-A1 SPIROPIPERIDINE DERIVATIVES 89Bio Ltd. (IL) 2019-10-23 EP disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 WO disclosed
EP-2311840-A1 Spirocyclic derivatives as histone deacetylase inhibitors DAC S.r.l. (IT) 2011-04-20 EP disclosed
EP-2271634-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2011-01-12 EP disclosed
US-20100317668-A1 SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-12-16 US disclosed
US-7803809-B2 Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2010-09-28 US disclosed
US-20100120774-A1 Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2010-05-13 US disclosed
EP-2167471-A1 SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2010-03-31 EP disclosed
WO-2009133107-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2009-11-05 WO disclosed
US-20090275602-A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2009-11-05 US disclosed
US-20090036478-A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2009-02-05 US disclosed
WO-2008147544-A1 SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120774-A1 Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use BACE1, APP, BACE2 AKR1C2 1164/4885AKR1C1 710/4885AKR1C3 298/4885
US-20090275602-A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use BACE1, BACE2, APP AKR1C2 1226/4885AKR1C1 932/4885AKR1C3 545/4885
US-11878982-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885
US-20100317668-A1 SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, APP, BACE2 AKR1C2 1164/4885AKR1C1 710/4885AKR1C3 298/4885
US-20090036478-A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use BACE1, BACE2, APP AKR1C2 1034/4885AKR1C1 752/4885AKR1C3 518/4885
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 AKR1C2 2647/4885AKR1C1 2684/4885AKR1C3 2153/4885
US-20210284651-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885
US-20240166661-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885
US-11046707-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 AKR1C2 49/4885AKR1C1 52/4885AKR1C3 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.